Key facts

Brief history

The company was founded in 1973 by Mr Smeets as a family-owned company at Deurne Belgium, and has from the beginning focused on the production of pharmaceutical powders.
Extension of the production area in 1987
In 2004, the company was bought by private investors, the name “Laboratoria Smeets” was kept.
Due to a strong growth in demand, a new site (Neerland site) was built in 2004, focussing on the mixing activities of powders and liquids. Our state of the art laboratory is also located at this site
In 2014 a third site was custom build for one customer.

About us

LABORATORIA SMEETS N.V.

Fotografielaan 42
B-2610 Antwerpen-Wilrijk
Tel. +32 (0)3 828 29 37
Fax +32 (0)3 830 21 36
e-mail: info@labosmeets.be

MENU

CORE ACTIVITIES

EN NL FR DE ES

CASE:

CASE: New Technology for API solubility
In collaboration with the University of Ghent, Labo Smeets has realised a new process in pharmaceutical extrusion technology, which enables us to make highly soluble granules. The main application is to make pharmaceutical granule compositions to drastically improve water solubility of active ingredients. The technology is applicable for the following drug ...

New Technology for API solubility
In collaboration with the University of Ghent, Labo Smeets has realised a new process in pharmaceutical extrusion technology, which enables us to make granules. The main application is to make pharmaceutical granule compositions to drastically improve water solubility of active ingredients. This equipment is installed and available since January 2011.

CASE: Flexibility
We were contacted by a company that had a large project based upon nasal therapy with essential oils. There was no supplier for the part, no clear definition of the product and no procedure lines to make the product, but there was a short deadline. Pressure in order to obtain the right information at the right timing. We agreed with the customer the precise ...

CASE: Product innovation
A customer identified a patented technology at one of the Belgian universities to make one of their products easier to administer. We were contacted at an early stage to help with developing the product. We jointly decided to set up a test manufacturing unit in order to produce small batches for the clinical trials. As the project outcome was uncertain, ...

CASE: Strategic procurement
One of our pharmacuetical customers is a large consumer of raw materials. Often large pharmaceutical customers are constrained with their raw materials procurement strategies. The complexity of the regulatory filing for many of their products, prevents them from obtaining the best deal. Underlying causes are the intrinsic speed of action, but also the ...